Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 14(1): 16016, 2024 Jul 11.
Article in English | MEDLINE | ID: mdl-38992004

ABSTRACT

Triple-negative breast cancer (TNBC) represents aggressive phenotype with limited treatment options due to the lack of drug targets. Natural compounds are extensively studied regarding their potential to alter the efficacy of cancer treatment Among them sulforaphane - an isothiocyanate of natural origin, was shown to be a hormetic compound, that may exert divergent effects: cytoprotective or cytotoxic depending on its concentrations. Thus, the aim of this study was to determine the effect of its low, dietary concentrations on the proliferation and migration of the TNBC cells in the in vivo and in vitro 2D and 3D model. Results of the in vivo experiment showed up to 31% tumor growth inhibition after sulforaphane treatment associated with lowered proliferating potential of cancer cells, reduced areas of necrosis, and changed immune cell type infiltration, showing less malignant type of tumor in contrast to the non-treated group. Also, the study revealed that sulforaphane decreased the number of lung metastases. The in vitro study confirmed that SFN inhibited cell migration, but only in cells derived from 3D spheroids, not from 2D in vitro cultures. The results show a specific role of sulforaphane in the case of cells released from the TNBC primary tumor and its environment.


Subject(s)
Cell Movement , Cell Proliferation , Isothiocyanates , Sulfoxides , Triple Negative Breast Neoplasms , Isothiocyanates/pharmacology , Isothiocyanates/administration & dosage , Triple Negative Breast Neoplasms/drug therapy , Triple Negative Breast Neoplasms/pathology , Sulfoxides/pharmacology , Female , Humans , Cell Movement/drug effects , Cell Line, Tumor , Animals , Cell Proliferation/drug effects , Mice , Anticarcinogenic Agents/pharmacology , Anticarcinogenic Agents/administration & dosage , Anticarcinogenic Agents/therapeutic use , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL
...